

# Tuberculosis profile: Singapore

Population 2021: 5.9 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	2 800 (2 400-3 300)	48 (41-55)
HIV-positive TB incidence	24 (14-37)	0.4 (0.23-0.62)
MDR/RR-TB incidence**	54 (39-69)	0.91 (0.66-1.2)
HIV-negative TB mortality	26 (22-30)	0.43 (0.36-0.5)
HIV-positive TB mortality	9 (5-13)	0.15 (0.09-0.22)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	1.9% (1.4-2.3)
Previously treated cases	2.7% (1.4-4.6)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	1% (1-1)

## TB case notifications, 2021

Total new and relapse	2 461
- % tested with rapid diagnostics at time of diagnosis	95%
- % with known HIV status	92%
- % pulmonary	82%
- % bacteriologically confirmed <sup>^</sup>	56%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	58%
Total cases notified	2 463

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	19	0.84%
- on antiretroviral therapy		

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	99%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	92%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	22
Patients started on treatment - MDR/RR-TB <sup>^^^</sup>	19
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	2
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>	2
MDR/RR-TB cases tested for resistance to any fluoroquinolone	18

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	79%	2 335
Previously treated cases, excluding relapse, registered in 2020	40%	5
HIV-positive TB cases registered in 2020	86%	21
MDR/RR-TB cases started on second-line treatment in 2019	44%	9
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	50%	2

## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	92% (68-100)

\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone


<sup>^</sup> Calculated for pulmonary cases only

<sup>^^</sup> Includes cases with unknown previous TB treatment history

<sup>^^^</sup> Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2021

(Number)



## Cases attributable to five risk factors, 2021

(Number)

